For patients with type 2 diabetes, Semaglutide can reduce the risk of major cardiovascular events, making it a valuable treatment option for those with or at risk of heart disease
Always check available stability information for the peptide being used
Sumida K, Nadkarni GN, Grams ME, Sang Y, Ballew SH, Coresh J, Matsushita K, Surapaneni A, Brunskill N, Chadban SJ, Chang AR, Cirillo M, Daratha KB, Gansevoort RT, Garg AX, Iacoviello L, Kayama T, Konta T, Kovesdy CP, Lash J, Lee BJ, Major RW, Metzger M, Miura K, Naimark D, Nelson RG, Sawhney S, Stempniewicz N, Tang M, Townsend RR, Traynor JP, Valdivielso JM, Wetzels J, Polkinghorne KR, Heerspink H
Levels of other mitochondrial proteins, like VDAC1 and N-Methyl-D-Aspartate Receptor Subunit 1 (NMDAR1), were decreased in both PACS groups (with and without NPs)